首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1623526

PGT（植入前基因檢測）市場：按產品類型、按週期類型、按技術、按程序類型、按應用、按最終用戶、按地區，2024-2031 年

Preimplantation Genetic Testing Market By Product, By Cycle Type, By Technology, By Procedure Type, By Application, By End-User, And Region for 2024- 2031

出版日期: 2024年10月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

PGT（植入前基因檢測）市場評估 - 2024-2031

人們對輔助生殖技術 (ART) 的認識和利用不斷提高，以及對遺傳異常和不孕症的擔憂不斷增加，正在推動 PGT（植入前基因檢測）市場的發展。Verified Market Research分析師表示，預計2031年PGT（植入前基因檢測）市場估值為13.3409億美元，低於2023年6.2191億美元的估值，預計將達到這一水準。

新一代定序 (NGS) 和陣列比較基因組雜交 (aCGH) 等基因組技術的進步使基因篩檢更加準確和全面，加速了市場成長。這將推動市場從2024年到2031年以10.01%的複合年增長率成長。

PGT（植入前基因檢測）市場定義/概述

植入前基因檢測（PGT）是針對體外受精（IVF）產生的胚胎的專門基因檢測過程。在將胚胎放入子宮之前，從每個胚胎中取出一個或幾個細胞進行活檢，以確定其基因組成。PGT主要用於發現胚胎中的遺傳異常、染色體異常或特定基因突變。

此外，這種方法對於有遺傳性遺傳疾病風險的夫妻、有反覆流產或體外受精失敗史的人以及尋求不孕症治療的老年婦女特別有用。PGT 可以選擇沒有遺傳疾病的胚胎，增加成功懷孕和健康孩子出生的機會。

影響PGT（植入前基因檢測）市場成長的推動因素有哪些？

基因檢測越來越受到公眾的歡迎，因為人們認識到它具有在受精卵的早期階段檢測遺傳異常和疾病的優勢。這種意識是由於人們對健康嬰兒的渴望不斷增加，尤其是有遺傳病史的夫婦、高齡母親或經歷過多次懷孕失敗的夫婦。這種保護子孫後代健康和福祉的願望一直是建立植入前基因檢測（PGT）的關鍵驅動力。

PGT（植入前基因檢測）市場從次世代定序（NGS）、聚合酶鍊式反應（PCR）和微陣列方法等基因檢測技術的進步中受益匪淺。這些技術提高了基因檢測的準確性、效率和速度，使 PGT 更容易取得且可靠。此外，IVF 設備和程序的進步正在支持改進基因檢測並促進將 PGT 納入不孕症治療。

此外，遺傳疾病的全球盛行率正在增加，部分原因是診斷方法的改善和認識的提高。已知有遺傳問題家族史或經歷過不明原因不孕、流產或死產的夫婦可能會選擇PGT，以減少將遺傳異常遺傳給孩子的機會。這些世代趨勢擴大了 PGT 服務的潛在消費者基礎，並促使市場成長。

倫理問題是否會限制 PGT（植入前基因檢測）的採用？

植入前基因檢測（PGT）是一種在懷孕前以體外受精（IVF）評估胚胎是否有遺傳問題的過程。這引發了人們對根據遺傳特徵選擇胚胎的倫理擔憂，並可能促使 "設計嬰兒" 的誕生。使用PGT來避免重大遺傳疾病和選擇理想的性狀之間存在一線之隔，並且存在關於優生學、不公正和偏見的社會、道德和倫理問題，從而限制了市場的成長。

儘管PGT技術已經取得了長足的進步，但它在準確性、效率以及檢測多種遺傳疾病的能力方面仍然存在局限性。出現假陽性和假陰性，導致存活胚胎被破壞或選擇未診斷的遺傳異常的胚胎。提高 PGT 的準確性和範圍需要持續的研究和開發，這既昂貴又耗時，限制了市場的擴張。

The growing awareness and use of assisted reproductive technologies (ART), along with increased occurrences of genetic abnormalities and infertility concerns, is propelling the preimplantation genetic testing (PGT) market. According to the analyst from Verified Market Research, the Preimplantation Genetic Testing Market is estimated to reach a valuation of USD 1334.09 Million in 2031 over the forecast subjugating around USD 621.91 Million valued in 2023.

Advancements in genomic technologies, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), are allowing for more precise and comprehensive genetic screening, accelerating market growth. It enables the market to grow at a CAGR of 10.01% from 2024 to 2031.

Preimplantation Genetic Testing Market: Definition/Overview

Preimplantation Genetic Testing (PGT) is a specialized genetic testing process for embryos generated through in vitro fertilization (IVF). Before being put into the uterus, one or a few cells from each embryo are biopsied to determine their genetic makeup. PGT is primarily used to discover genetic abnormalities, chromosomal problems, or specific genetic mutations in embryos, allowing prospective parents to make educated decisions about embryo selection for implantation.

Furthermore, this method is especially useful for couples at risk of passing on genetic illnesses, individuals with a history of recurrent pregnancy loss or unsuccessful IVF attempts, and older women seeking fertility treatments. PGT allows for the selection of embryos free of genetic diseases, boosting the chances of a successful pregnancy and the birth of a healthy child.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Influencing the Growth of the Preimplantation Genetic Testing Market?

Genetic testing is gaining popularity among the general public, owing to a better understanding of its benefits in detecting genetic abnormalities and ailments early in the embryonic stage. This awareness is accompanied by a rising preference for healthy babies, particularly among couples with a history of genetic diseases, those of advanced maternal age, or those who have experienced several pregnancy losses. This desire to protect future generations' health and well-being is an important driver to establishing preimplantation genetic testing (PGT).

The Preimplantation Genetic Testing Market has profited greatly from advances in genetic testing technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarray methods. These technologies have increased the accuracy, efficiency, and speed of genetic testing, making PGT more accessible and dependable. Furthermore, advances in IVF equipment and procedures support these genetic testing improvements, making it easier to incorporate PGT into fertility treatments.

Furthermore, the global prevalence of genetic illnesses is increasing, owing in part to improved diagnosis procedures and more awareness. Couples with known genetic problems in their families, as well as those who have had unexplained infertility, miscarriages, or stillbirths, are more likely to choose PGT to lower the possibility of transferring genetic abnormalities to their children. This generational trend broadens the potential consumer base for PGT services, resulting in market growth.

Will Ethical Concerns Restrain Adoption of Preimplantation Genetic Testing?

Preimplantation genetic testing (PGT) is the process of evaluating embryos for genetic problems before to pregnancy using in vitro fertilization. This raises ethical concerns about selecting embryos based on genetic features, which might lead to "designer babies." There is a narrow line between utilizing PGT to avoid major genetic illnesses and choosing desirable features, which creates social, moral, and ethical concerns about eugenics, injustice, and prejudice, thereby limiting market growth.

While PGT technologies have made tremendous advances, they still have limits in terms of accuracy, efficiency, and capacity to detect a wide spectrum of genetic disorders. False positives or negatives occur, resulting in the destruction of viable embryos or the selection of embryos with undiagnosed genetic abnormalities. Improving the accuracy and scope of PGT necessitates continual research and development, which is expensive and time-consuming, limiting market expansion.

Category-wise Acumens

How does the Dominance of the Reagents and Consumables Impact the Market?

According to VMR analyst, the reagents and consumables segment is anticipated to dominate the segment within the Preimplantation Genetic Testing Market. Reagents and consumables are required at all stages of the PGT process, from DNA amplification to analysis. These items are used in big quantities and require regular replenishment, resulting in a steady demand. Unlike instruments, which are long-term capital investments, reagents and consumables are continuing operating expenses for genetic testing laboratories. This large volume utilization greatly increases their market share.

The field of genetic testing, including PGT, is quickly growing, with ongoing advances and breakthroughs in reagents and consumables. These advancements have the potential to improve the accuracy, speed, and efficiency of testing processes. Also, the flexibility to tailor reagents and consumables to specific tests or conditions helps accelerate their adoption, addressing the precise requirements of PGT laboratories and clinics.

Furthermore, reagents and consumables are used in a variety of PGT procedures, including Preimplantation Genetic Screening (PGS) for aneuploidy detection, Preimplantation Genetic Diagnosis (PGD) for single gene diseases, and newer approaches for structural rearrangements and mitochondrial illnesses. These products' market domination is due to their adaptability and requirement in a variety of PGT applications.

How does the Rising Awareness of Genetic Disorders Contribute to the PGD Segment?

The preimplantation genetic diagnosis (PGD) segment is estimated to hold the largest share of the Preimplantation Genetic Testing Market during the forecast period. PGD is utilized specifically by couples who are known to have a high chance of passing on specific genetic disorders to their children. This specialized approach to testing detects single-gene disorders and chromosomal anomalies unique to the parents' genetic origins, making it an essential tool for families looking to avoid the transfer of hereditary diseases. The need for PGD stems from its capacity to bring peace of mind to at-risk couples by ensuring the birth of healthy offspring free of specific genetic abnormalities.

Furthermore, the general public and healthcare professionals are becoming increasingly aware of the benefits of genetic testing in preventing inherited disorders. This awareness, combined with the rising occurrence of genetic abnormalities due to a variety of reasons, including longer parental ages at conception, has resulted in increased demand for PGD. Prospective parents are becoming more knowledgeable and proactive about their reproductive options, resulting in an increase in the use of PGD to assure the health and well-being of their future offspring.

Country/Region-wise Acumens

How will Demand for Preimplantation Genetic Testing Shape the North American Market?

According to VMR analysis, the North American region is estimated to dominate in Preimplantation Genetic Testing Market during the forecast period. Genetic testing and its benefits are widely understood and accepted in North America. This is due in part to healthcare providers' educational efforts, patient group activism, and media and popular culture coverage. As a result, there is a high demand for genetic testing services, including PGT, among people and couples seeking to uncover genetic abnormalities, assess risks to future children, and make educated reproductive decisions. This desire is amplified by the cultural acceptance of IVF and related reproductive technologies.

Furthermore, North America, particularly the United States, has some of the world's most advanced healthcare infrastructure, with cutting-edge medical facilities, leading-edge research institutions, and a strong emphasis on new healthcare solutions. This infrastructure facilitates considerable research and development efforts in genetic testing and reproductive technologies. Furthermore, substantial healthcare expenditure in the region, both public and private, allows for significant investment in new technology and treatments, making modern PGT services broadly available to patients.

Will the Asia Pacific prove Opportunistic for the Preimplantation Genetic Testing Market?

Asia Pacific is estimated to grow at the highest CAGR in the Preimplantation Genetic Testing Market. This region has experienced substantial growth in awareness and acceptance of genetic testing and its potential advantages. This is attributable to improved knowledge, more access to information via digital platforms, and government-led initiatives to promote genetic health. As a result, more people and couples are using PGT as part of their family planning, increasing market demand.

Furthermore, governments around Asia Pacific are making significant investments in healthcare infrastructure as well as encouraging biotechnology and genetic engineering research. Countries such as China, Japan, South Korea, and Singapore are setting the standard for enacting policies that encourage the adoption of modern medical technology, including PGT. These measures, combined with supporting legislative frameworks, are considerably boosting the region's PGT market.

Competitive Landscape

The competitive landscape of the preimplantation genetic testing (PGT) market is marked by a constant interplay of technology breakthroughs, regulatory frameworks, and shifting customer preferences. Furthermore, cooperation among healthcare providers, research institutions, and technology companies are pushing innovation and broadening the use of PGT beyond typical genetic disorders to include broader genomic profiling.

Some of the prominent players operating in the Preimplantation Genetic Testing Market include:

Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, Igenomix.

Latest Developments:

In April 2023, Eurofins Genoma, a leader in the PGT market, launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. This new test analyses cell-free foetal DNA in the maternal bloodstream, providing a less intrusive option for couples undergoing in vitro fertilization (IVF).

In April 2023, LifeView, powered by Genomic Prediction, announced a partnership with Ovation Fertility. This agreement gives Ovation patients access to the LifeView PGT Platform, which provides cutting-edge technology and might significantly improve their clinical care experience.

1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETIC TESTING MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT

5.1 Overview
5.2 Reagents and Consumables
5.3 Instruments
5.4 Software and Services

6 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY CYCLE TYPE

6.1 Overview
6.2 Fresh Non-donor
6.3 Frozen Non-donor
6.4 Fresh Donor
6.5 Frozen Donor

7 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

7.1 Overview
7.2 Next-generation Sequencing (NGS)
7.3 Polymerase Chain Reaction (PCR)
7.4 Fluorescence In Situ Hybridization
7.5 Comparative Genomic Hybridization
7.6 Single-nucleotide Polymorphism

8 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

8.1 Overview
8.2 Preimplantation Genetic Screening
8.3 Preimplantation Genetic Diagnosis

9 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

9.1 Overview
9.2 Aneuploidy
9.3 Structural Chromosomal Abnormalities
9.4 Single Gene Disorders
9.5 X-linked Disorders
9.6 HLA Typing
9.7 Gender Identification

10 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

10.1 Overview
10.2 Fertility Clinics
10.3 Hospitals
10.4 Diagnostic Laboratories
10.5 Other End Users

11 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

11.1 Overview
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.2.3 Mexico
11.3 Europe
- 11.3.1 Germany
- 11.3.2 U.K.
- 11.3.3 France
- 11.3.4 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Rest of Asia Pacific
11.5 Rest of the World
- 11.5.1 Latin America
- 11.5.2 Middle East and Africa

12 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET COMPETITIVE LANDSCAPE

12.1 Overview
12.2 Company Market Share
12.3 Vendor Landscape
12.4 Key Development Strategies

13 COMPANY PROFILES

13.1 Illumina, Inc.
- 13.1.1 Overview
- 13.1.2 Financial Performance
- 13.1.3 Product Outlook
- 13.1.4 Key Developments
13.2 Thermo Fisher Scientific Inc.
- 13.2.1 Overview
- 13.2.2 Financial Performance
- 13.2.3 Product Outlook
- 13.2.4 Key Developments
13.3 Agilent Technologies, Inc.
- 13.3.1 Overview
- 13.3.2 Financial Performance
- 13.3.3 Product Outlook
- 13.3.4 Key Developments
13.4 Perkinelmer, Inc.
- 13.4.1 Overview
- 13.4.2 Financial Performance
- 13.4.3 Product Outlook
- 13.4.4 Key Developments
13.5 Coopersurgical, Inc.
- 13.5.1 Overview
- 13.5.2 Financial Performance
- 13.5.3 Product Outlook
- 13.5.4 Key Developments
13.6 Abbott Laboratories
- 13.6.1 Overview
- 13.6.2 Financial Performance
- 13.6.3 Product Outlook
- 13.6.4 Key Developments
13.7 Natera, Inc.
- 13.7.1 Overview
- 13.7.2 Financial Performance
- 13.7.3 Product Outlook
- 13.7.4 Key Developments
13.8 Rubicon Genomics
- 13.8.1 Overview
- 13.8.2 Financial Performance
- 13.8.3 Product Outlook
- 13.8.4 Key Developments
13.9 Oxford Gene Technology
- 13.9.1 Overview
- 13.9.2 Financial Performance
- 13.9.3 Product Outlook
- 13.9.4 Key Developments
13.10 Yikon Genomics
- 13.10.1 Overview
- 13.10.2 Financial Performance
- 13.10.3 Product Outlook
- 13.10.4 Key Developments
13.11 Scigene
- 13.11.1 Overview
- 13.11.2 Financial Performance
- 13.11.3 Product Outlook
- 13.11.4 Key Developments
13.12 Beijing Genomics Institute
- 13.12.1 Overview
- 13.12.2 Financial Performance
- 13.12.3 Product Outlook
- 13.12.4 Key Developments
13.13 Good Start Genetics
- 13.13.1 Overview
- 13.13.2 Financial Performance
- 13.13.3 Product Outlook
- 13.13.4 Key Developments
13.14 Invicta Genetics
- 13.14.1 Overview
- 13.14.2 Financial Performance
- 13.14.3 Product Outlook
- 13.14.4 Key Developments
13.15 Combimatrix
- 13.15.1 Overview
- 13.15.2 Financial Performance
- 13.15.3 Product Outlook
- 13.15.4 Key Developments
13.16 Genea Limited
- 13.16.1 Overview
- 13.16.2 Financial Performance
- 13.16.3 Product Outlook
- 13.16.4 Key Developments
13.17 Progenesis
- 13.17.1 Overview
- 13.17.2 Financial Performance
- 13.17.3 Product Outlook
- 13.17.4 Key Developments